NCT02848300

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Evaluation of Local Pharmacokinetics and Tolerability of Bimatoprost Applied Topically to the Scalp of Male Patients With Androgenetic Alopecia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Allergan · Industry
• Sex: Male
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

Detailed description

Single-center, multiple-dose study evaluting the local pharmacokinetics and tolerability of bimatoprost following 14 days of once daily topical administration of bimatoprost Formulation A and Formulation B (both containing 1% bimatoprost) to the scalp of male patients With androgenetic alopecia

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	Bimatoprost 1% Formulation A	Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
DRUG	Bimatoprost 1% Formulation B	Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.

Timeline

• Start date: 2016-07-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2016-07-28
• Last updated: 2016-10-26

Locations

1 site across 1 country: United States